From innovation to therapeutic care
Go faster for Sickle Cell Disease patients
INNOVHEM
A based-Genopole company founded on breakthrough innovation,
INNOVHEM is developing solutions that will both promote the development and optimization of use of treatments for the most common genetic disease over the world, sickle cell disease.
Our Mission
Transform clinical care to improve patients quality of life
Our proposition
Combining innovative biomarkers with AI
Combining biomarkers adapted to Red Blood Cell diseases with AI,
INNOVHEM is developping solutions, which make possible to optimize the care of patients:
-
Improving the development of effective treatments
-
Offering personalized therapy for each patients
The Biomarkers
Fetal Hemoglobin per Red Blood Cell
- Related to the pathophysilogy of Sickle Cell Disease
- Accurate
A new method to dose intra-vascular hemolysis
- Direct
- Accurate
The Team
A leadership on Sickle Cell Disease
Laura Bencheikh
Project Manager
Ils nous soutiennent
Région Ile de France
Evry, Région Ile de France
MEDICEN PARIS REGION
News
INNOVHEM is very pleased to announce the start of a preclinical Investigator Sponsored Trial with funding support by Jazz Pharmaceuticals, to support the development of new treatments for sickle cell disease
November, 27, 2020